Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure

Circulation

Volumn 125, Issue 22, 2012, Pages 2739-2750

  Meissner, Anja ^a   Yang, Jingli ^a   Kroetsch, Jeffrey T ^a   Sauvé, Meghan ^a   Dax, Hendrik ^a   Momen, Abdul ^c   Noyan Ashraf, M Hossein ^a,c   Heximer, Scott ^a,b   Husain, Mansoor ^a,b   Lidington, Darcy ^a,d   Bolz, Steffen Sebastian ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Heart and Stroke/Richard Lewar Centre of Excellence for Cardiovascular Research   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acute myocardial infarction; Hemodynamics; Myogenic vasoconstriction; Signal transduction; Vasomotor tone

Indexed keywords

SPHINGOSINE 1 PHOSPHATE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HEART; HEART FAILURE; IN VITRO STUDY; ISOLATED ARTERY; LUNG; MESENTERIC ARTERY; MOUSE; NONHUMAN; POSTERIOR CEREBRAL ARTERY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; BRAIN; CELLS, CULTURED; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEART FAILURE; LUNG; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; SIGNAL TRANSDUCTION; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861854722     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.047316     Document Type: Article

References (39)

1. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407. (Pubitemid 36565571)
2. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, Spiegel S, Pohl U. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of rhoA/rho kinase. Circulation. 2003;108:342-347. (Pubitemid 36899027)
3. Peter BF, Lidington D, Harada A, Bolz HJ, Vogel L, Heximer S, Spiegel S, Pohl U, Bolz SS. Role of sphingosine-1-phosphate phosphohydrolase 1 in the regulation of resistance artery tone. Circ Res. 2008;103:315-324.
4. Hoefer J, Azam MA, Kroetsch JT, Poi HL, Momen MA, Voigtlaender-Bolz J, Scherer EQ, Meissner A, Bolz SS, Husain M. Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction. Circ Res. 2010;107:923-933.
5. Yang J, Meissner A, Lidington D, Bolz SS. TNF enhances cerebral microvascular tone during congestive heart failure via activation of sphingosine kinase 1. Can J Cardiol. 2009;25:179.
6. Pyne S, Lee SC, Long J, Pyne NJ. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 2009;21:14-21.
7. Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S. Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta. 2002; 1582:8-17. (Pubitemid 34634106)
8. Le Stunff H, Galve-Roperh I, Peterson C, Milstien S, Spiegel S. Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J Cell Biol. 2002;158:1039-1049.
9. Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, Hannun YA, Obeid LM. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem. 2001;276:35258-35264.
10. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol. 2009;158:982-993.
11. Skoura A, Hla T. Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res. 2009;82:221-228.
12. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489-503.
13. Lorenz JN, Arend LJ, Robitz R, Paul RJ, MacLennan AJ. Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol. 2007;292:R440-R446. (Pubitemid 46089859)
14. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res. 2002;91:151-157. (Pubitemid 34827226)
15. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, Basu S, Old LJ. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA. 1997;94:8093-8098. (Pubitemid 27343782)
16. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH. An animal model for cystic fibrosis made by gene targeting. Science. 1992;257:1083-1088.
17. Peest U, Sensken SC, Andreani P, Hanel P, Van Veldhoven PP, Graler MH. S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem. 2008;104:756-772. (Pubitemid 351830827)
18. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, Marino CR, de Jonge HR, Bijman J, Scholte BJ. A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest. 1996;98: 1304-1312. (Pubitemid 26322055)
19. Wamhoff BR, Lynch KR, Macdonald TL, Owens GK. Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2008;28:1454-1461.
20. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:3C-8C. (Pubitemid 40755512)
21. Doyama K, Fujiwara H, Fukumoto M, Tanaka M, Fujiwara Y, Oda T, Inada T, Ohtani S, Hasegawa K, Fujiwara T, Sasayama S. Tumour necrosis factor is expressed in cardiac tissues of patients with heart failure. Int J Cardiol. 1996;54:217-225. (Pubitemid 26226634)
22. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant. 1998;17:356-362. (Pubitemid 28196954)
23. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ, Vadas MA. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA. 1998;95:14196-14201. (Pubitemid 28549344)
24. Radeff-Huang J, Seasholtz TM, Chang JW, Smith JM, Walsh CT, Brown JH. Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression. J Biol Chem. 2007;282:863-870. (Pubitemid 47076562)
25. Donati C, Nincheri P, Cencetti F, Rapizzi E, Farnararo M, Bruni P. Tumor necrosis factor-alpha exerts pro-myogenic action in C2C12 myoblasts via sphingosine kinase/S1P2 signaling. FEBS Lett. 2007;581: 4384-4388. (Pubitemid 47368198)
26. Wang Y, Loo TW, Bartlett MC, Clarke DM. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J. 2007;406:257-263. (Pubitemid 47310956)
27. Thibodeau PH, Richardson JM III, Wang W, Millen L, Watson J, Mendoza JL, Du K, Fischman S, Senderowitz H, Lukacs GL, Kirk K, Thomas PJ. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem. 2010;285:35825-35835.
28. Jiang Q, Engelhardt JF. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Eur J Hum Genet. 1998;6:12-31. (Pubitemid 28101694)
29. Lidington D, Peter BF, Meissner A, Kroetsch JT, Pitson SM, Pohl U, Bolz SS. The phosphorylation motif at serine 225 governs the localization and function of sphingosine kinase 1 in resistance arteries. Arterioscler Thromb Vasc Biol. 2009;29:1916-1922.
30. Labombarda F, Pellissier A, Ellafi M, Creveuil C, Ribault V, Laurans M, Guillot M, Bergot E, Grollier G, Milliez P, Zalcman G, Saloux E. Myocardial strain assessment in cystic fibrosis. J Am Soc Echocardiogr. 2011;24:1037-1045.
31. Koelling TM, Dec GW, Ginns LC, Semigran MJ. Left ventricular diastolic function in patients with advanced cystic fibrosis. Chest. 2003;123: 1488-1494. (Pubitemid 36549767)
32. Super M, Irtiza-Ali A, Roberts SA, Schwarz M, Young M, Smith A, Roberts T, Hinks J, Heagerty A. Blood pressure and the cystic fibrosis gene: evidence for lower pressure rises with age in female carriers. Hypertension. 2004;44:878-883. (Pubitemid 39577415)
33. Teichgräber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Döoring G, Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med. 2008;14:382-391. (Pubitemid 351499396)
34. Baudouin-Legros M, Hinzpeter A, Jaulmes A, Brouillard F, Costes B, Fanen P, Edelman A. Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3UTR part of transcripts. Am J Physiol. 2005;289:C1240-C1250. (Pubitemid 41456840)
35. Nakamura H, Yoshimura K, Bajocchi G, Trapnell BC, Pavirani A, Crystal RG. Tumor necrosis factor modulation of expression of the cystic fibrosis transmembrane conductance regulator gene. FEBS Lett. 1992;314: 366-370. (Pubitemid 23005691)
36. Bartoszewski R, Rab A, Twitty G, Stevenson L, Fortenberry J, Piotrowski A, Dumanski JP, Bebok Z. The mechanism of cystic fibrosis transmembrane conductance regulator transcriptional repression during the unfolded protein response. J Biol Chem. 2008;283:12154-12165.
37. Brouillard F, Bouthier M, Leclerc T, Clement A, Baudouin-Legros M, Edelman A. NF-kappa B mediates up-regulation of CFTR gene expression in Calu-3 cells by interleukin-1beta. J Biol Chem. 2001;276: 9486-9491.
38. Scherer EQ, Yang J, Canis M, Reimann K, Ivanov K, Diehl CD, Backx PH, Wier WG, Strieth S, Wangemann P, Voigtlaender-Bolz J, Lidington D, Bolz SS. TNF-enhances microvascular tone and reduces blood flow in the cochlea via enhanced S1P signaling. Stroke. 2010;41:2618-2624.
39. Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, D'Andrea RJ, Gamble JR, Vadas MA. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem. 2002;277:7996-8003. (Pubitemid 34968251)